Innovations and furtherance Cancer Care
00
Days
:
00
Hrs
:
00
Min
:
00
Sec
The Ohio State University
Ohio
Dr. Jessica Fleming received her Ph.D. in Molecular, Cellular, and Developmental Biology from The Ohio State University in 2012, where her dissertation focused on identifying genetic factors that predisposed individuals to skin cancer. After completing her degree, she joined Dr. Arnab Chakravarti’s laboratory in the Department of Radiation Oncology at the Ohio State University. Upon joining, she began work on identifying predictive molecular biomarkers of radiation treatment response in prostate cancer. From this work, a predictive molecular model of salvage radiation therapy, incorporating two microRNAs, Gleason score, and lymph node status was developed. Since then she has transitioned her focus to pediatric and adult CNS tumors and is interested in identifying molecular biomarkers of tumor progression and treatment resistance. The overall goal of her translational research is to not only better understand the underlying biological mechanisms of treatment resistance and tumor progression of CNS tumors but to pinpoint novel targetable pathways. She hopes that her work can lead to the development of molecular-based clinical assays to help guide treatment planning as well as the development of novel therapeutic strategies for patients, resulting in better survival rates and improved quality of life. Her expertise spans multiple areas of high-throughput, next-generation, genomic and molecular profiling approaches and has helped develop a refined pipeline for correlative molecular studies with a translational research team, comprised of trained researchers, clinicians, statisticians, and bioinformaticians. She is actively involved with the NRG Oncology/RTOG clinical trials cooperative group and is an active lead on the Ohio State University Radiation Oncology International Team. Additionally, her work has been presented at conferences across the United States and worldwide.
2006-2012 The Ohio State University, Ph.D., Molecular, Cellular, and Developmental Biology.
2002-2006 Ashland University, Bachelor of Science, Biology, Cum Laude.
2018 Best of ASTRO Award; Basic/Translational Science Abstract Award, Sr.Investigator Clinical Category.
2012 Alumni Grants for Graduate Research and Scholarship Award The Ohio State University.
2009-2010 Up on the Roof Fellowship The Ohio State University.
2006 Graduated Cum Laude Ashland University.
2002-2006 Presidential Scholar Ashland University.
2002-2006 Track and Field Athletic Scholar Ashland University.
2005 NSF REU Fellow College of Charleston.
Meng W, Efstathiou J, Singh R, McElroy J, Volinia S, Cui R, Ibrahim A, Johnson B, Gupta N, Satvam M, Wang H, Miller E, Nguyen P, Fleming J, Wu C, Haque JS, Shipley W, Chakravarti A. MicroRNA biomarkers for patients with muscle-invasive bladder cancer undergoing selective bladder sparing Trimodality treatment. 2019. Int J Radiat Oncol Biol Phys. (Epub ahead of print). PMID: 30583038.
Moran NE, Thomas-Ahner JM, Fleming JL, McElroy JP, Mehl R, Grainger EM, Riedl KM, Toland AE, Schwartz SJ, and Clinton SK. Single Nucleotide Polymorphisms in β-carotene Oxygenase 1 are Associated with Plasma Lycopene Responses to a Tomato-Soy Juice Intervention in Men with Prostate Cancer. 2018. J Nutr. 149: 381-397. PMID: 30801647.
Beyer S, Bell EH, McElroy J, Fleming J, Cui T, Becker A, Bassett E, Johnson B, Gulati P, Popp I, Staszewski O, Prinz M, Grosu A, Haque SJ, and Chakravarti A. Oncogenic Transgelin-2 is Differentially Regulated in Isocitrate Dehydrogenase Wild-type vs. Mutant Gliomas. 2018. Oncotarget. 9:37097-37111 (Epub ahead of print) PMID: 30647847.
Cui T, Bell EH, McElroy J, Becker A, Gulati P, Geurts M, Mladkova N, Gray A, Liu K, Yang L, Liu L, Fleming JL, Haque SJ, Barnholtz-Sloan J, Ligon K, Beroukhim R, Robe P, and Chakravarti A. miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma. 2018. Oncogene. (Epub ahead of print) PMID: 30559405
Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty A, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu HM, Laack NN, Schultz CJ, Gray HJ, Robins HI, Mehta MP, Chakravarti A. MGMT promoter methylation status independently predicts survival outcomes in NRG Oncology RTOG 0424: a phase II trial of temozolomide-based chemoradiotherapy for high-risk low-grade gliomas. 2018. JAMA Oncology. 4:1405-1409. PMID: 29859803.
Beyer S, Fleming J, Meng W, Singh R, Haque SJ, Chakravarti A. The Role of miRNAs in Angiogenesis, Invasion, and Metabolism and Their Therapeutic Implications in Gliomas. 2017. Cancers (Basel). 9: pin E85. PMID: 28698530.
Bell EH, Kirste S, Fleming JL, Stegmaier P, Drendel V, Mo X, Ling S, Fabian D, Manring I, Jilg CA, Schultze-Seemann W, McNulty M, Zynger DL,Martin D, White J, Werner M, Grosu AL, Chakravarti A. A Novel miRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy. 2015. PLoS One. Mar 11;10(3):e0118745.
Fleming JL, Dworkin AM, Zhang M, Qureshi, AA, Allain DC, Fernandez S, Wei L, Peters S, Iwenofu OH, Ridd K, Bastian BC, Han J, Toland AE. Allelic specific imbalance mapping identifies HDAC9 and IFRD1 as candidate susceptibility genes for cutaneous squamous cell carcinoma. 2014. Int J Cancer. 134: 244-248.
Fleming JL, Gable, DL, Samadzadeh-Tarighat S, Gillespie JL, Schultz NP, Toland AE. Differential expression of miR-1, a putative tumor suppressing microRNA, in cancer resistant and cancer-susceptible mice. 2013. PeerJ. 1:e68.
Skeeles LE, Fleming JL, Mahler KL, Toland AE. The impact of 3’UTR variants on differential expression of candidate cancer susceptibility genes. 2013.PLoS One. 8: e58609.
Fleming JL, Phiel CJ, Toland AE. The role of oxidative stresses in aberrant DNA methylation in Alzheimer’s Disease. 2011. Curr. Alzheimer Res. 2012. 9: 1077-1096.
Mahler KL, Fleming JL, Dworkin AM, Gladman N, Cho H-Y, Mao JH, Balmain A, Toland AE. Sequence divergence of Musset's and Mus Musculus across a skin cancer susceptibility locus. 2008 BMC Genomics. 9: 1-12.
Fleming JL, Huang TH, Toland AE. The role of parental and grandparental epigenetic alterations in familial cancer risk. 2008. Cancer Res. 68: 9116-21.
DeLorenzo ME, Fleming, J. Individual and Mixture Effects of Selected Pharmaceuticals and Personal Care Products on the Marine Phytoplankton Species Dunaliellatertiolecta. 2007. Arch Environ Contam Toxicol. 54: 203-10.
2018 Society for Neuro-Oncology (SNO); New Orleans, LA, USA The Role of miR-219a-2-3p as a Tumor Suppressor in IDH1/2-Wild-Type Gliomas Jessica Fleming, Erica Hlavin Bell, Zhen-Yue Tong, Ivana Grozdic, Joseph McElroy, Sasha Beyer, Denise Fabian, Tiantian Cui, Ilinca Popp, Ori Staszewski, Marco Prinz, S. Jaharul Haque, Anca Grosu, and Arnab Chakravarti (Poster Presentation and Abstract).
2018 American Society for Radiation Oncology (ASTRO); San Antonio, TX, USA Elevated MGMT Gene Expression is Independently Associated with Worse Overall Survival in NRG Oncology/RTOG 9813: A Phase III Study of Radiation Therapy (RT) and Temozolomide (TMZ) Versus RT and Nitrosourea (NU) in Anaplastic Grade III Glioma Jessica Fleming, Joseph McElroy, Erica Bell, Susan Chang, Emad Youssef, Grant Hunter, WK Alfred Yung, Steven Howard, Joseph Bovi, Jean-Paul Bahary, Helen Shih, Rachel Abrams Rabinovitch, Yuhchyau Chen, Peixin Zhang, Arnab Chakravarti (Oral Presentation and Abstract; Best of ASTRO Award; Basic/Translational Science Abstract Award, Sr.Investigator (Clinical Category))
2018 NRG Oncology; Philadelphia, PA, USA Prognostic and Predictive RNA Biomarkers in NRG Oncology/RTOG 9802
Jessica L. Fleming (Oral Presentation).
2018 NRG Oncology; Phoenix, AZ, USA Comprehensive Gene Expression Analysis in NRG Oncology/RTOG 9813: A phase III study of RT + temozolomide (TMZ) versus RT+nitrosourea (NU) in grade III anaplastic astrocytoma Jessica L. Fleming (Oral Presentation).
2017 Invitation to Speak at Institut Gustave Roussy, Paris France A Novel miRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy Jessica L. Fleming (Invited Oral Presentation).
2017 Invitation to Speak at Centre Oscar Lambert, Lille France A Novel miRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy Jessica L. Fleming (Invited Oral Presentation).
2017 Society for Neuro-Oncology (SNO); San Francisco, CA, USA Predictive significance of IDH1/2 mutation and 1p/19q co-deletion status in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas Erica H. Bell, Peixin Zhang, Edward G. Shaw, Jan C. Buckner, Geoffrey R. Barger, Stephen W. Coons, Dennis E. Bullard, Minesh P. Mehta, Mark R. Gilbert, Paul D. Brown, Keith J. Stelzer, Jessica Fleming, Joseph P. McElroy, Cynthia D. Timmers, Aline P. Becker, Andrea L. Salavaggione, Ziyan Liu, Kenneth Aldape, David G. Brachman, Stanley Z. Gertler, Albert D. Murtha, Christopher J. Schultz, David Johnson, Ian R. Crocker, Arnab Chakravarti (Oral Presentation and Abstract; Best of ASTRO Award; Basic/Translational Science Abstract Award, Sr.Investigator (Clinical Category))
2017 Society for Neuro-Oncology (SNO); San Francisco, CA, USA Molecular Profiling Identified Increased Transgelin-2 in IDH WT vs. IDH Mutant Gliomas Sasha Beyer, Erica Hlavin Bell, Joseph McElroy, Oliver Oehlke, Jessica Fleming, Aline Becker, Tian-tian Cui, Ori Staszewski, Marco Prinz, Anca Grosu, S. Jaharul Haque, and Arnab Chakravarti (Poster Presentation and Abstract).
2017 III Annual Clinical Sciences and Drug Discovery (CSDD) International Conference; Washington, DC, USA The Clinical Implementation of Molecular Biomarkers in Glioma Jessica L. Fleming (Invited Oral Presentation).
2017 American Society for Radiation Oncology (ASTRO); San Diego, CA, USA MGMT promoter methylation status independently predicts overall survival in NRG Oncology/RTOG 9813: a phase III trial of radiation plus nitrosourea vs radiation plus temozolomide in anaplastic astrocytoma Erica H. Bell, Minhee Won, Susan M. Chang, Gregory Cairncross, Mark R. Gilbert, Jean-Paul Bahary, Carol A. Dolinskas, Kenneth D. Aldape, Joseph McElroy, Jessica Fleming, Lynn S. Ashby, Helen A. Shih, Grant K. Hunter, Alfred W. K. Yung, Steven P. Howard, Andre Robidoux, Malika L. Siker, Brian D. Kavanagh, Yuhchyau Chen, Arnab Chakravarti (Oral Presentation and Abstract).
2017 World Federation of Neuro-Oncology Societies (WFNOS); Zurich, Switzerland MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas Erica Bell, Peixin Zhang, Kenneth D. Aldape, Joseph McElroy, Minesh P. Mehta, Jessica Fleming, Ziyan Liu, Stephen Coons, David Johnson, Arnab Chakravarti (Oral Presentation and Abstract).
2017 American Society of Clinical Oncology (ASCO); Chicago, IL, USA Comprehensive assessment of ATRX mutation, ATRX protein expression, and the alternative lengthening of telomere (ALT) Phenotype in grade II and grade III astrocytomas
Aline P. Becker, Erica H. Bell, Jessica Fleming, Joseph McElroy, Denise Fabian, Sasha Beyer, Andrea Salavaggione, Mindy K. Graham, Christopher M. Heaphy, Oliver Oehlke, Ori Staszewski, Marco Prinz, Anca Grosu, Arnab Chakravarti (Poster Presentation and Abstract).
2017 NRG Oncology; Philadelphia, PA, USA Prognostic and Predictive RNA Biomarkers in NRG Oncology/RTOG 9802
Jessica L. Fleming (Oral Presentation).
2017 European Society for Radiotherapy and Oncology (ESTRO), Vienna, Austria An Overview of Translational Research in the Laboratory of Dr. Arnab Chakravarti Jessica L. Fleming (Invited Oral Presentation).
2017 OSU CCC-James Annual Scientific Meeting; Columbus, OH, USA The role of miR-601 in prostate cancer progression
Jessica L. Fleming, Erica Hlavin Bell, Kathryn Andrews, and Arnab Chakravarti (Poster Presentation and Abstract).
2017 American Association for Cancer Research (AACR); Washington, DC, USA The role of miR-601 in prostate cancer progression Jessica L. Fleming, Erica Hlavin Bell, Kathryn Andrews, and Arnab Chakravarti (Poster Presentation and Abstract)
2017 NRG Oncology; Houston, TX, USA.
A comprehensive genomic and prognostic analysis in NRG Oncology/RTOG 9802: a phase III trial of radiation vs radiation plus PCV in high-risk LGG. Erica H. Bell, Peixin Zhang, Edward G. Shaw, Jan C. Buckner, Geoffrey R. Barger, Stephen W. Coons, Dennis E. Bullard, Minesh P. Mehta, Mark R. Gilbert, Paul D. Brown, Keith J. Stelzer, Joseph P. McElroy, Jessica Fleming, Aline Paixao Becker, Kenneth D. Aldape, David G. Brachman, Albert D. Murtha, Christopher J. Schultz, David Johnson, Stanley Z. Gertler, Nadia N. Laack, Maria Werner-Wasik, Ian R. Crocker, Arnab Chakravarti (Oral Presentation).
2016 Invitation to Speak at All India Institute of Medical Science (AIIMS), New Delhi, India A Novel miRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy Jessica L. Fleming (Invited Oral Presentation).
2016 Invitation to Speak at TATA Memorial Hospital, Mumbai, India Novel miRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy Jessica L. Fleming (Invited Oral Presentation)
2016 Society for Neuro-Oncology (SNO); Scottsdale, AZ, USA 1p/19q codeletion status predicts survival outcomes in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas Erica H. Bell, Peixin Zhang, Edward G. Shaw, Jan C. Buckner, Geoffrey R. Barger, Stephen W. Coons, Dennis E. Bullard, Minesh P. Mehta, Mark R. Gilbert, Paul D. Brown, Keith J. Stelzer, Joseph P. McElroy, Jessica Fleming, Arup Chakraborty, Aline Paixao Becker, Kenneth D. Aldape, David G. Brachman, Albert D. Murtha, Christopher J. Schultz, David Johnson, Stanley Z. Gertler, Nadia N. Laack, Maria Werner-Wasik, Ian R. Crocker, Arnab Chakravarti (Poster Presentation and Abstract).
2016 Society for Neuro-Oncology (SNO); Scottsdale, AZ, USA MGMT Status predicts survival outcomes in NRG Oncology/RTOG 0424: a phase II trial of temozolomide-base chemoradiotherapy for high-risk low-grade gliomas Erica H. Bell, Peixin Zhang, Barbara J. Fisher, David R. Macdonald, Joseph P. McElroy, Glenn J. Lesser, Jessica Fleming, Arup Chakraborty, Ziyan Liu, Aline Paixao Becker, Denise Fabian, Kenneth D. Aldape, Lynn S. Ashby, Maria Werner-Wasik, Eleanor M. Walker, Jean-Paul Bahary, Young Kwok, Michael Yu, Nadia N. Laack, Christopher J. Schultz, Heidi J. Gray, H. Ian Robins, Minesh P. Mehta and Arnab Chakravarti (Poster Presentation and Abstract).
2016 Society for Neuro-Oncology (SNO); Scottsdale, AZ, USA Comprehensive survival analysis of MGMT protein by traditional and quantitative fluorescence immunohistochemistry compared to MGMT promoter methylation in a large institutional glioblastoma cohort treated with the Stupp protocol. Aline Paixao Becker, Erica H Bell, Joseph P McElroy, Tiantian Cui, Marjolein Geurts, Jessica Fleming, Arup Chakraborty, Ziyan Liu, Pierre Robe, Arnab Chakravarti (Poster Presentation and Abstract).
2016 Society for Neuro-Oncology (SNO); Scottsdale, AZ, USA Automated Quantitative Analysis (AQUA) as a reliable method to asses MGMT expression in glioblastomas. Aline Paixao Becker, Erica H Bell, Joseph P McElroy, Tiantian Cui, Marjolein Geurts, Jessica Fleming, Arup Chakraborty, Ziyan Liu, Pierre Robe, Arnab Chakravarti (Poster Presentation and Abstract).
2016 OSU Translational Therapeutic Program Retreat A Novel miRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy Bell EH, Kirste S, Fleming JL, Stegmaier P, Drendel V, Mo X, Ling S, Fabian D, Manring I, Jilg CA, Schultze-Seemann W, McNulty M, Zynger DL, Martin D, White J, Werner M, Grosu AL, Chakravarti A. (Oral Presentation and Abstract).
2016 American Society for Radiation Oncology (ASTRO); Boston, MA, USA A Mutation and Prognostic Biomarker Study in Grade II and III Gliomas Utilizing a Combined Cohort of NRG Oncology/RTOG 9802 and 9813 Erica H Bell, Joseph P McElroy, Jessica Fleming, Cynthia Timmers, Arup R Chakraborty, Andrea L Salavaggione, Susan M Chang, Edward G Shaw, Kenneth D Aldape, David G Brachman, Christopher J Schultz, Helen A Shih, Mark Curtis, Grant K Hunter, Albert D Murtha, Peixin Zhang, Minhee Won, Minesh P Mehta, Arnab Chakravarti (Oral Presentation and Abstract).
2016 American Society for Radiation Oncology (ASTRO); Boston, MA, USA Personalized Prognostic microRNA Models for Lower Grade Gliomas Jessica Fleming, Erica Hlavin Bell, Oliver Oehlke, Joseph McElroy, Denise Fabian, Sasha Beyer, Andrea Salavaggione, Ori Staszewski, Marco Prinz, Anca Grosu, and Arnab Chakravarti (Oral Presentation and Abstract).
2016 American Society of Clinical Oncology (ASCO); Chicago, IL, USA Comprehensive mutation analysis in NRG Oncology/RTOG 9802 (a phase III study of RT vs RT + PCV in high-risk low-grade gliomas (LGGs)) Erica Hlavin Bell, Joseph P McElroy, Jessica Fleming, Cynthia Dawn Timmers, Arup R Chakraborty, Andrea L Salavaggione, Edward G. Shaw, Kenneth D. Aldape, David Brachman, Albert D Murtha, Minhee Won, Minesh P. Mehta & Arnab Chakravarti (Poster Presentation and Abstract).
2016 NRG Oncology; Dallas, TX, USA Beyond IDH: Prognostic Molecular Biomarkers in Grade II/III Gliomas
Jessica L. Fleming (Oral Presentation).
2016 Invitation to Speak at Fukushima Medical University Hospital, Fukushima, Japan An Overview of Translational Research in the Laboratory of Dr. Arnab Chakravarti Jessica L. Fleming (Invited Oral Presentation).
2016 Invitation to Speak at Kyoto University, Kyoto, Japan An Overview of Translational Research in the Laboratory of Dr. Arnab Chakravarti Jessica L. Fleming (Invited Oral Presentation).
2016 Invitation to Speak at Gunma University, Gunma, Japan An Overview of Translational Research in the Laboratory of Dr. Arnab Chakravarti Jessica L. Fleming (Invited Oral Presentation).
2016 Invitation to Speak at University of Tsukuba, Tsukuba, Japan An Overview of Translational Research in the Laboratory of Dr. Arnab Chakravarti Jessica L. Fleming (Invited Oral Presentation).
2016 OSUWMC 1st Annual Department of Pathology Research Retreat; Columbus, OH, USA Genome-wide profiling reveals distinct prognostic classes among WHO grade II/III gliomas Erica Hlavin Bell*, Oliver Oehlke*, Jessica Fleming, Arup Chakraborty, Joseph P. McElroy, Cynthia Timmers, Andrea Salavaggione, Ori Staszewski, Marco Prinz, Anca L. Grosu, Arnab Chakravarti (Oral Presentation and Abstract).
2016 15th Annual OSU COM Trainee Research Day; Columbus, OH, USA The role of miR-601 in prostate cancer progression
Jessica L. Fleming*, Erica Hlavin Bell*, Kathryn Andrews, and Arnab Chakravarti (Poster Presentation and Abstract).
2016 European Society for Radiotherapy and Oncology (ESTRO), Turin, Italy Identification and Clinical Implication of Novel Prognostic and Predictive Molecular Signatures and Biomarkers in Brain, Prostate and H&N Cancer. Jessica L. Fleming (Invited Oral Presentation).
2016 American Association for Cancer Research (AACR); New Orleans, Louisiana, USA The role of miR-601 in prostate cancer progression Jessica L. Fleming*, Erica Hlavin Bell*, Kathryn Andrews, and Arnab Chakravarti (Poster Presentation and Abstract).
2016 NRG Oncology; Atlanta, GA, USA Prognostic and predictive genetic alterations in 9813 and 9802
Jessica L. Fleming (Oral Presentation).
2015 Invitation to Speak at University of Turku, Turku, Finland A Novel miRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy Jessica L. Fleming (Invited Oral Presentation).
2015 Society for Neuro-Oncology (SNO); San Antonio, TX, USA Next-generation sequencing reveals distinct prognostic classes among grade II/III gliomas Erica Hlavin Bell, Oliver Oehlke, Jessica Fleming, Arup Chakraborty, Joe McElroy, Cynthia Timmers, Andrea Salavaggione, Ori Staszewski, Marco Prinz, Anca Grosu, Arnab Chakravarti (Poster Presentation and Abstract).
2015 14th Annual OSU COM Trainee Research Day; Columbus, OH, USA A Novel miRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy Bell EH*, Kirste S*, Fleming JL*, Stegmaier P, Drendel V, Mo X, Ling S, Fabian D, Manring I, Jilg CA, Schultze-Seemann W, McNulty M, Zynger DL,Martin D, White J, Werner M, Grosu AL, Chakravarti A. (Poster Presentation and Abstract).
2015 American Association for Cancer Research (AACR); Philadelphia, PA, USA A Novel miRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy Bell EH*, Kirste S*, Fleming JL*, Stegmaier P, Drendel V, Mo X, Ling S, Fabian D, Manring I, Jilg CA, Schultze-Seemann W, McNulty M, Zynger DL,Martin D, White J, Werner M, Grosu AL, Chakravarti A. (Poster Presentation and Abstract).
2015 NanoString Seminar: Genomics Shared Resource - Comprehensive Cancer Center; Columbus, OH, USA Personalized Predictive Models for Prostate Cancer Therapies Jessica L. Fleming (Invited Oral Presentation).
2015 American College of Radiation Oncology (ACRO) Meeting. A novel miRNA-based predictive model for biochemical failure following prostatectomy and post-prostatectomy salvage radiation therapy. Hlavin Bell, E., Kirste, S., Stegmaier, P., Fleming, J., Brendel, V., Mo, X., Ling, S., Fabian, D., Manring, I., Jilg, C.A., Schultze-Seemann, W., McNulty, M., Zynger, D.L., Martin D., White, J., Werner, M., Grosu, A., and Chakravarti, A. (Oral Presentation and Abstract).
2015 NRG Meeting; San Diego, CA, USA Personalized Prognostic and Predictive microRNA Models for Low-Grade Gliomas
Jessica L. Fleming (Oral Presentation).
2014 World Cancer Congress (WCC) Meeting; Nanjing China Taking a Genome-Wide Approach to Unveil Novel Molecular Biomarkers in Prostate Carcinoma Jessica L. Fleming (Invited Oral Presentation).
2014 American College of Radiation Oncology (ACRO) Meeting; Orlando FL, USA The Identification of Molecular Biomarkers in Prostate Carcinoma Erica H. Bell, Simon Kirste, Petra Stegmaier, Jessica L. Fleming, Stella Ling, Kirsteen H. Maclean, Xiaokui Mu, Vanessa Drendel, Anca L. Grosu, and Arnab Chakravarti (Abstract and Poster Presentation).
2012 Integrated Graduate Program (IGP) Symposium; Columbus OH, USA Allelic specific imbalance mapping identifies HDAC9 and IFRD1 as candidate susceptibility genes for cutaneous squamous cell carcinoma. Jessica L. Fleming, Amy M. Dworkin, Mingfeng Zhang, Abrar A. Qureshi, Dawn C Allain, Soledad Fernandez, Lai Wei, Sara Peters, O. Hans Iwenofu, Katie Ridd, Boris C. Bastian, Jiali Han, Amanda Ewart Toland (Oral Presentation and Abstract).
2012 OSUMC 11th Annual Graduate & Postgraduate Research Day; Columbus OH, USA Allelic specific imbalance mapping identifies HDAC9 and IFRD1 as candidate susceptibility genes for cutaneous squamous cell carcinoma. Jessica L. Fleming, Amy M. Dworkin, Mingfeng Zhang, Abrar A. Qureshi, Dawn C Allain, Soledad Fernandez, Lai Wei, Sara Peters, O. Hans Iwenofu, Katie Ridd, Boris C. Bastian, Jiali Han, Amanda Ewart Toland (Poster Presentation and Abstract).
2012 American Association for Cancer Research (AACR); Chicago IL, USA Allelic specific imbalance mapping identifies HDAC9 and IFRD1 as candidate susceptibility genes for cutaneous squamous cell carcinoma. Jessica L. Fleming, Amy M. Dworkin, Mingfeng Zhang, Abrar A. Qureshi, Dawn C Allain, Soledad Fernandez, Lai Wei, Sara Peters, O. Hans Iwenofu, Katie Ridd, Boris C. Bastian, Jiali Han, Amanda Ewart Toland (Oral Presentation and Abstract).
2011 Integrated Graduate Program (IGP) Symposium; Columbus OH, USA Identification of Genetic Risk Factors for Cutaneous Squamous Cell Carcinoma Susceptibility on Chromosome 7 Jessica L. Fleming, Amy M. Dworkin, Boris Bastian, Allan Balmain, and Amanda Ewart Toland (Oral Presentation and Abstract).
2011 American Association for Cancer Research (AACR); Orlando FL, USA Ets1 as a Target of MicroRNA-1 in Cutaneous Squamous Cell Carcinoma Dustin L. Gable, Jessica L. Fleming, Amanda E.Toland (Poster Presentation and Abstract).
2011 American Association for Cancer Research (AACR); Orlando FL, USA DCPS as a tumor suppressor in cutaneous squamous cell carcinoma Kelsey M. Gray, Amy M. Dworkin, Jessica L. Fleming, Amanda Ewart Toland (Poster Presentation and Abstract).
2011 OSUMC 10th Annual Graduate & Postgraduate Research Day; Columbus OH, USA Identification of Genetic Risk Factors for Cutaneous Squamous Cell Carcinoma Susceptibility on Chromosome 7 Jessica L. Fleming, Amy M. Dworkin, Boris Bastian, Allan Balmain, and Amanda Ewart Toland (Poster Presentation and Abstract).
2011 OSUMC Comprehensive Cancer Center 13th Annual Scientific Meeting; Columbus OH, USA Identification of Genetic Risk Factors for Cutaneous Squamous Cell Carcinoma Susceptibility on Chromosome 7 Jessica L. Fleming, Amy M. Dworkin, Boris Bastian, Allan Balmain, and Amanda Ewart Toland (Poster Presentation and Abstract).
2010 American Society of Human Genetics (ASHG); Washington DC, USA Identification of Genetic Risk Factors for Cutaneous Squamous Cell Carcinoma Susceptibility on Chromosome 7 Jessica L. Fleming, Amy M. Dworkin, Boris Bastian, Allan Balmain, Amanda Ewart Toland (Poster Presentation and Abstract)
2010 Integrated Graduate Program (IGP) Symposium; Columbus OH, USA Testing Ahr, and Hdac9 for a Role in Cutaneous Squamous Cell Carcinoma Susceptibility Jessica L. Fleming, Laura Skeeles, Kimberly Mahler, Jian-Hua Mao, Allan Balmain, and Amanda Ewart Toland (Poster Presentation and Abstract).
2010 OSUMC 9th Annual Graduate & Postgraduate Research Day; Columbus OH, USA Dustin L. Gable, Jessica L. Fleming, and Amanda E. Toland The transcription factor oncogene, Ets1, as a potential target of the tumor suppressor, microRNA-1, in cutaneous squamous cell carcinoma (Poster Presentation and Abstract).
2009 OSUMC Comprehensive Cancer Center 11th Annual Scientific Meeting; Columbus OH, USA Testing Ahr and Hdac9 for a Role in Cutaneous Squamous Cell Carcinoma Susceptibility Jessica L. Fleming, Kimberly Mahler, Laura Skeeles, Jian-Hua Mao, Allan Balmain, and Amanda Ewart Toland (Poster Presentation and Abstract).
2009 OSUMC 8th Annual Graduate & Postgraduate Research Day; Columbus OH, USA Testing Ahr, and Hdac9 for a Role in Cutaneous Squamous Cell Carcinoma Susceptibility Jessica L. Fleming, Kimberly Mahler, Laura Skeeles, Jian-Hua Mao, Allan Balmain, and Amanda Ewart Toland (Poster Presentation and Abstract).
2009 OSUMC Molecular Biology Cancer Genetics (MBCG) Biannual Retreat; Perrysville OH, USA Testing Ahr and Hdac9 for a Role in Cutaneous Squamous Cell Carcinoma Susceptibility Jessica L. Fleming, Kimberly Mahler, Laura Skeeles, Jian-Hua Mao, Allan Balmain, and Amanda Ewart Toland (Poster Presentation and Abstract).
2008 OSUMC 7th Annual Graduate & Postgraduate Research Day; Columbus OH, USA Testing Candidate Genes for a Role in the Risk of Cutaneous Squamous Cell Carcinoma Jessica L. Fleming, Kimberly Mahler, Jian-Hua Mao, Allan Balmain, and Amanda Ewart Toland (Poster Presentation and Abstract).
2008 OSUMC Comprehensive Cancer Center 10th Annual Scientific Meeting; Columbus OH, USA Testing Candidate Genes for a Role in the Risk of Cutaneous Squamous Cell Carcinoma Jessica L. Fleming, Kimberly Mahler, Jian-Hua Mao, Allan Balmain, and Amanda Ewart Toland (Poster Presentation and Abstract).
2007 OSUMC Molecular Biology Cancer Genetics (MBCG) Biannual Retreat; Perrysville OH, USA Testing Candidate Genes for a Role in the Risk of Cutaneous Squamous Cell Carcinoma Jessica L. Fleming, Kimberly Mahler, Jian-Hua Mao, Allan Balmain, and Amanda Ewart Toland (Poster Presentation and Abstract).
2005 Meeting of Ecological Society of America; Montreal, Canada Early Evidence for Diel Horizontal Migration of Daphnia in Dimictic Site Lake, OH P.A. Saunders, J. Fleming, K. Carlson, and T. Miller (Poster Presentation and Abstract)
2005 Fort Johnson Undergraduate Summer Research Forum; Charleston SC, USA Individual and Mixture Effects of Selected Pharmaceuticals and Personal Care Products on the Marine Phytoplankton Species Dunaliellatertiolecta Marie E. DeLorenzo and Jessica Fleming (Oral Presentation and Abstract)
2005 Ashland University Undergraduate Research Forum; Ashland OH, USA Assessment of Behavioral Migratory Pattern of Daphnia P.A. Saunders, J. Fleming, K. Carlson, and T. Miller (Poster Presentation and Abstract)
Turn on Reminders
Your reminder was set successfully
